Skip to main content

Vaxil Bio Ltd(VXL-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.140
Day High0.160
Open:0.140
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Vaxil Bio Ltd

Select a category then submit the form to load news
GlobeNewswire
Vaxil Announces Close of Previously Announced Non-Brokered Private Placement and Update on Board of Directors
GlobeNewswire
Vaxil Announces Non-Brokered Private Placement
AI-generated - The Globe and Mail
Vaxil Bio: Top 10 Undervalued Biotechnology Industry Stocks (VXL)
AI-generated - The Globe and Mail
Vaxil Bio: Top 10 Undervalued Biotechnology Industry Stocks (VXL)
GlobeNewswire
VAXIL: SHARE CONSOLIDATION
GlobeNewswire
VAXIL’s Annual and Special Shareholders Meeting
GlobeNewswire
Vaxil Bio Proposed Reverse Takeover With Green Date Terminated
GlobeNewswire
Vaxil Bio Enters Into Definitive Agreement With Green Data Centers for Reverse Take Over
AI-generated - The Globe and Mail
Vaxil Bio: Top 10 Undervalued Biotechnology Industry Stocks (VXL)
AI-generated - The Globe and Mail
Vaxil Bio: Top 10 Undervalued Biotechnology Industry Stocks (VXL)
GlobeNewswire
Vaxil Bio Enters Into Letter of Intent With Green Data in Respect of A Proposed Reverse Takeover
AI-generated - The Globe and Mail
Vaxil Bio: Top 10 Undervalued Biotechnology Industry Stocks (VXL)
AI-generated - The Globe and Mail
Vaxil Bio: Top 10 Undervalued Biotechnology Industry Stocks (VXL)
AI-generated - The Globe and Mail
Vaxil Bio: Bottom 25 Performing Stocks Year-to-Date on TSX-V (VXL)
GlobeNewswire
Vaxil Bio Proposed Reverse Takeover with Copper Bullet Terminated and Update of Research Activities
GlobeNewswire
Vaxil Bio Enters Into Letter of Intent With Copper Bullet Mines in Respect of a Proposed Reverse Takeover
AI-generated - The Globe and Mail
Vaxil Bio: Top 10 Undervalued Biotechnology Industry Stocks (VXL)
GlobeNewswire
Vaxil Provides Update on Research Activities and Management Changes
The Globe and Mail
Vaxil Bio: Top 10 Undervalued Biotechnology Industry Stocks (VXL)
The Globe and Mail
Vaxil Bio: Bottom 25 Performing Stocks Year-to-Date on TSX-V (VXL)
The Globe and Mail
Vaxil Bio: Bottom 25 Performing Stocks Year-to-Date on TSX-V (VXL)
The Globe and Mail
Vaxil Bio: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (VXL)
The Globe and Mail
Vaxil Bio: Top 10 Undervalued Biotechnology Industry Stocks (VXL)
The Globe and Mail
Vaxil Bio: Bottom 25 Performing Stocks Year-to-Date on TSX-V (VXL)
The Globe and Mail
Vaxil Bio: Bottom 25 Performing Stocks Year-to-Date on TSX-V (VXL)
The Globe and Mail
Vaxil Bio: Bottom 25 Performing Stocks Year-to-Date on TSX-V (VXL)
The Globe and Mail
Vaxil Bio: Bottom 25 Performing Stocks Year-to-Date on (VXL)
The Globe and Mail
Vaxil Bio VXL-X is in the bottom 25 performing stocks year-to-date on the TSX Venture Exchange
The Globe and Mail
Vaxil Bio VXL is in the bottom 25 performing stocks year-to-date on the TSX Venture Exchange
The Globe and Mail
Vaxil Bio VXL is in the bottom 25 performing stocks year-to-date on the TSX Venture Exchange
The Globe and Mail
Vaxil Bio VXL is in the bottom 25 performing stocks year-to-date on the TSX Venture Exchange

Profile

Vaxil Bio Ltd is an Israeli immunotherapy biotech company focused on a novel drug discovery and development platform based on Signal Peptides which the company deploys to fight infectious diseases and cancer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.